BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia

Journal of Immunology

Volumn 176, Issue 8, 2006, Pages 5108-5116

  Boissel, Nicolas ^a,b   Rea, Delphine ^a,b   Tieng, Vannary ^a,b   Dulphy, Nicolas ^a,b   Brun, Manuel ^a,b   Cayuela, Jean Michel ^c   Rousselot, Philippe ^a,d   Tamouza, Ryad ^a,b   Le Bouteiller, Philippe ^e   Mahon, François Xavier ^f   Steinle, Alexander ^g   Charron, Dominique ^a,b   Dombret, Hervé ^a   Toubert, Antoine ^a,b  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ PARIS DIDEROT   (France)

^c Laboratoire Central d'Hematologie   (France)

^d CENTRE HOSPITALIER DE VERSAILLES   (France)

^e CHU PURPAN   (France)

^f BORDEAUX UNIVERSITY HOSPITAL   (France)

^g UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; BCR ABL PROTEIN; CD34 ANTIGEN; IMATINIB; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NATURAL KILLER CELL RECEPTOR NKG2D; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; RNA 18S; SMALL INTERFERING RNA;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CD8+ T LYMPHOCYTE; CELL STRAIN K 562; CHRONIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NATURAL KILLER T CELL; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TUMOR IMMUNOLOGY; WESTERN BLOTTING;

EID: 33645767415     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.8.5108     Document Type: Article

References (56)

1. Bauer, S., V. Groh, J. Wu, A. Steinle, J. H. Phillips, L. L. Lanier, and T. Spies. 1999. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285: 727-729.
2. Wu, J., Y. Song, A. B. Bakker, S. Bauer, T. Spies, L. L. Lanier, and J. H. Phillips. 1999. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285: 730-732.
3. Groh, V., A. Steinle, S. Bauer, and T. Spies. 1998. Recognition of stress-induced MHC molecules by intestinal epithelial γδ T cells. Science 279: 1737-1740.
4. Zwirner, N. W., K. Dole, and P. Stastny. 1999. Differential surface expression of MICA by endothelial cells, fibroblasts, keratinocytes, and monocytes. Hum. Immunol. 60: 323-330.
5. Groh, V., R. Rhinehart, H. Secrist, S. Bauer, K. H. Grabstein, and T. Spies. 1999. Broad tumor-associated expression and recognition by tumor-derived γδ T cells of MICA and MICB. Proc. Natl. Acad. Sci. USA 96: 6879-6884.
6. Pende, D., P. Rivera, S. Marcenaro, C. C. Chang, R. Biassoni, R. Conte, M. Kubin, D. Cosman, S. Ferrone, L. Moretta, et al. 2002. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res. 62: 6178-6186.
7. Cerwenka, A., J. L. Baron, and L. L. Lanier. 2001. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc. Natl. Acad. Sci. USA 98: 11521-11526.
8. Diefenbach, A., E. R. Jensen, A. M. Jamieson, and D. H. Raulet. 2001. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413: 165-171.
9. Groh, V., J. Wu, C. Yee, and T. Spies. 2002. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419: 734-738.
10. Wu, J. D., L. M. Higgins, A. Steinle, D. Cosman, K. Haugk, and S. R. Plymate. 2004. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J. Clin. Invest. 114: 560-568.
11. Salih, H. R., H. G. Rammensee, and A. Steinle. 2002. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J. Immunol. 169: 4098-4102.
12. Coudert, J. D., J. Zimmer, E. Tomasello, M. Cebecauer, M. Colonna, E. Vivier, and W. Held. 2005. Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells. Blood 106: 1711-1717.
13. Jinushi, M., T. Takehara, T. Tatsumi, T. Kanto, V. Groh, T. Spies, T. Suzuki, T. Miyagi, and N. Hayashi. 2003. Autocrine/paracrine IL-15 that is required for type I IFN-mediated dendritic cell expression of MHC class I-related chain A and B is impaired in hepatitis C virus infection. J. Immunol. 171: 5423-5429.
14. Groh, V., S. Bahram, S. Bauer, A. Herman, M. Beauchamp, and T. Spies. 1996. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc. Natl. Acad. Sci. USA 93: 12445-12450.
15. Gasser, S., S. Orsulic, E. J. Brown, and D. H. Raulet. 2005. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436: 1186-1190.
16. Salih, H. R., H. Antropius, F. Gieseke, S. Z. Lutz, L. Kanz, H. G. Rammensee, and A. Steinle. 2003. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 102: 1389-1396.
17. Goldman, J. M., and J. V. Melo. 2003. Chronic myeloid leukemia: advances in biology and new approaches to treatment. N. Engl J. Med. 349: 1451-1464.
18. Terme, M., C. Borg, F. Guilhot, C. Masurier, C. Flament, E. F. Wagner, S. Caillat-Zucman, A. Bernheim, A. G. Turhan, A. Caignard, et al. 2005. BCR/ ABL promotes dendritic cell-mediated natural killer cell activation. Cancer Res. 65: 6409-6417.
19. Mahon, F. X., M. W. Deininger, B. Schultheis, J. Chabrol, J. Reiffers, J. M. Goldman, and J. V. Melo. 2000. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96: 1070-1079.
20. Tieng, V., C. Le Bouguenec, L. du Merle, P. Bertheau, P. Desreumaux, A. Janin, D. Charron, and A. Toubert. 2002. Binding of Escherichia coli adhesin AfaE to CD55 triggers cell-surface expression of the MHC class 1-related molecule MICA. Proc. Natl. Acad. Sci. USA 99: 2977-2982.
21. Scherr, M., K. Battmer, T. Winkler, O. Heidenreich, A. Ganser, and M. Eder. 2003. Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood 101: 1566-1569.
22. Druker, B. J., M. Talpaz, D. J. Resta, B. Peng, E. Buchdunger, J. M. Ford, N. B. Lydon, H. Kantarjian, R. Capdeville, S. Ohno-Jones, et al. 2001. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344: 1031-1037.
23. Baron, F., A. G. Turhan, J. Giron-Michel, B. Azzarone, M. Bentires-Alj, V. Bours, J. H. Bourhis, S. Chouaib, and A. Caignard. 2002. Leukemic target susceptibility to natural killer cytotoxicity: relationship with BCR-ABL expression. Blood 99: 2107-2113.
24. Buchdunger, E., C. L. Cioffi, N. Law, D. Stover, S, Ohno-Jones, B. J. Druker, and N. B. Lydon. 2000. Abl protein-tyrosine kinase inhibitor ST1571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 295: 139-145.
25. Skorski, T., P. Kanakaraj, M. Nieborowska-Skorska, M. Z. Ratajczak, S. C. Wen, G. Zon, A. M. Gewirtz, B. Perussia, and B. Calabretta. 1995. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 86: 726-736.
26. Ly, C., A. F. Arechiga, J. V. Melo, C. M. Walsh, and S. T. Ong. 2003. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Cancer Res. 63: 5716-5722.
27. Molinero, L. L., M. B. Fuertes, L. Fainboim, G. A. Rabinovich, and N. W. Zwirner. 2003. Up-regulated expression of MICA on activated T lymphocytes involves Lck and Fyn kinases and signaling through MEK1/ERK, p38 MAP kinase, and calcineurin. J. Leukocyte Biol. 73: 815-822.
28. Dan, S., M. Naito, and T. Tsuruo. 1998. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR-ABL tyrosine kinase, CGP 57148. Cell Death Differ. 5: 710-715.
29. Raulet, D. H. 2003. Roles of the NKG2D immunoreceptor and its ligands. Nat. Rev. Immunol. 3: 781-790.
30. Raffaghello, L., I. Prigione, I. Airoldi, M. Camoriano, I. Levreri, C. Gambini, D. Pende, A. Steinle, S. Ferrone, and V. Pistoia. 2004. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia 6: 558-568.
31. Lee, J. C., K. M. Lee, D. W. Kim, and D. S. Heo. 2004. Elevated TGF-β1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J. Immunol. 172: 7335-7340.
32. Doubrovina, E. S., M. M. Doubrovin, E. Vider, R. B. Sisson, R. J. O'Reilly, B. Dupont, and Y. M. Vyas. 2003. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J. Immunol. 171: 6891-6899.
33. Baccarani, M., D. Russo, G. Rosti, and G. Martinelli. 2003. Interferon-α for chronic myeloid leukemia. Semin. Hematol. 40: 22-33.
34. Barrett, J. 2003. Allogeneic stem cell transplantation for chronic myeloid leukemia. Semin. Hematol. 40: 59-71.
35. Molldrem, J. J., P. P. Lee, C. Wang, K. Felio, H. M. Kantarjian, R. E. Champlin, and M. M. Davis. 2000. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat. Med. 6: 1018-1023.
36. + progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 95: 2198-2203.
37. + T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 102: 2892-2900.
38. Burchert, A., S. Wolfl, M. Schmidt, C. Brendel, B. Denecke, D. Cai, L. Odyvanova, T. Lahaye, M. C. Muller, T. Berg, et al. 2003. Interferon-α, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood 101: 259-264.
39. Reuben, J. M., B. N. Lee, H. Johnson, H. Pritsche, H. M. Kantarjian, and M. Talpaz. 2000. Restoration of Thl cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-α. Clin. Cancer Res. 6: 1671-1677.
40. Boissel, N., P. Rousselot, E. Raffoux, J. M. Cayuela, O. Maarek, D. Charron, L. Degos, H. Dombret, A. Toubert, and D. Rea. 2004. Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate. Leukemia 18: 1656-1661.
41. Sconocchia, G., M. Lau, M. Provenzano, K. Rezvani, W. Wongsena, H. Fujiwara, N. Hensel, J. Melenhorst, J. Li, S. Ferrone, et al. 2005. The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions. Blood 106: 3666-3672.
42. Dietz, A. B., L. Souan, G. J. Knutson, P. A. Bulur, M. R. Litzow, and S. Vuk-Pavlovic. 2004. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 104: 1094-1099.
43. Borg, C., M. Terme, J. Taieb, C. Menard, C. Flament, C. Robert, K. Maruyama, H. Wakasugi, E. Angevin, K. Thielemans, et al. 2004. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J. Clin. Invest. 114: 379-388.
44. Appel, S., A. Rupf, M. M. Weck, O. Schoor, T. H. Brummendorf, T. Weinschenk, F. Grunebach, and P. Brossart. 2005. Effects of imatinib on monocyte-derived dendritic cells are mediated by inhibition of nuclear factor-κB and Akt signaling pathways. Clin. Cancer Res. 11: 1928-1940.
45. Diefenbach, A., and D. H. Raulet. 2002. The innate immune response to tumors and its role in the induction of T-cell immunity. Immunol. Rev. 188: 9-21.
46. Groh, V., A. Bruhl, H. El-Gabalawy, J. L. Nelson, and T. Spies. 2003. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 100: 9452-9457.
47. Ruggero, D., and P. P. Pandolfi. 2003. Does the ribosome translate cancer? Nat. Rev. Cancer 3: 179-192.
48. Perrotti, D., and B. Calabretta. 2004. Translational regulation by the p210 BCR/ ABL oncoprotein. Oncogene 23: 3222-3229.
49. Holland, E. C., N. Sonenberg, P. P. Pandolfi, and G. Thomas. 2004. Signaling control of mRNA translation in cancer pathogenesis. Oncogene 23: 3138-3144.
50. Bjornsti, M. A., and P. J. Houghton. 2004. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer 4: 335-348.
51. Perrotti, D., V. Cesi, R. Trotta, C. Guerzoni, G. Santilli, K. Campbell, A. Iervolino, F. Condorelli, C. Gambacorti-Passerini, M. A. Caligiuri, et al. 2002. BCR-ABL suppresses C/EBPα expression through inhibitory action of hnRNP E2. Nat. Genet. 30: 48-58.
52. Trotta, R., T. Vignudelli, O. Candini, R. V. Intine, L. Pecorari, C. Guerzoni, G. Santilli, M. W. Byrom, S. Goldoni, L. P. Ford, et al. 2003. BCR/ABL activates mdm2 mRNA translation via the La antigen. Cancer Cell 3: 145-160.
53. Spies, T. 2002. Induction of T cell alertness by bacterial colonization of intestinal epithelium. Proc. Natl. Acad. Sci. USA 99: 2584-2586.
54. Huang, S., M. A. Bjornsti, and P. J. Houghton. 2003. Rapamycins: mechanism of action and cellular resistance. Cancer Biol. Ther. 2: 222-232.
55. Mohi, M. G., C. Boulton, T. L. Gu, D. W. Sternberg, D. Neuberg, J. D. Griffin, D. G. Gilliland, and B. G. Neel. 2004. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc. Natl. Acad. Sci. USA 101: 3130-3135.
56. Recher, C., O. Beyne-Rauzy, C. Demur, G. Chicanne, C. Dos Santos, V. M. Mas, D. Benzaquen, G. Laurent, F. Huguet, and B. Payrastre. 2005. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 105: 2527-2534.